Literature DB >> 32721038

Clinical characteristics and outcomes of 2019 novel coronavirus disease patients presenting with initial gastrointestinal symptoms in Wuhan, China: A retrospective cohort study.

Shihua Luo1, Zhiqing Deng2, Xiaochun Zhang3, Zhenyu Pan2, Haibo Xu3.   

Abstract

BACKGROUND AND AIM: Patients with 2019 novel coronavirus disease (COVID-19) could present with gastrointestinal symptoms without fever or respiratory manifestations, which could be overlooked by health-care providers. We aimed to evaluate the clinical characteristics of COVID-19 in patients presenting with initial gastrointestinal symptoms.
METHODS: We evaluated all confirmed cases of COVID-19 in Zhongnan Hospital of Wuhan University between January 10 and February 29, 2020. We divided these patients into two groups: patients with initial gastrointestinal symptoms (group A, n = 183) and patients with respiratory syndrome and/or fever (group B, n = 1228). The clinical characteristics, radiological features, and laboratory data were assessed.
RESULTS: The clinical procedures of both groups underwent 1-2 weeks rising period and were downward trend at 3 weeks; less than 5% of patients progressed to critical illness. In both groups, mean leukocyte count (P = 0.354) and lymphocyte count (P = 0.386) were below normal, and C-reactive protein level was elevated (P = 0.412). There was mild liver function injury (aspartate aminotransferase, 65.8 ± 12.7 vs 67.4 ± 9.3 U/L, P = 0.246; alanine aminotransferase, 66.4 ± 13.2 vs 69.6 ± 12.7 U/L, P = 0.352), and normal renal function was intact (blood urea nitrogen 6.4 ± 2.5 vs 5.6 ± 2.8 mmol/L P = 0.358; creatinine 85.7 ± 37.2, 91.2 ± 32.6 μmol/L, P = 0.297). After a series of treatment, 176 and 1169 were stable and alive in groups A and B, respectively. The survival rate did not differ significantly between the groups (P = 0.313).
CONCLUSION: COVID-19 patients presented with initial gastrointestinal symptoms had similar clinical characteristics and outcomes, when compared with patients with fever and respiratory symptoms.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  COVID-19; Gastrointestinal symptoms; Pneumonia

Year:  2020        PMID: 32721038     DOI: 10.1111/jgh.15199

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

Review 1.  Gastrointestinal manifestations and possible mechanisms of COVID-19 in different periods.

Authors:  Meng Meng Zhang; Lu Ni Chen; Jia Ming Qian
Journal:  J Dig Dis       Date:  2021-12-12       Impact factor: 3.366

2.  Are gastrointestinal symptoms associated with higher risk of Mortality in COVID-19 patients? A systematic review and meta-analysis.

Authors:  Yang Wang; Yimin Li; Yifan Zhang; Yun Liu; Yulan Liu
Journal:  BMC Gastroenterol       Date:  2022-03-07       Impact factor: 3.067

3.  The Role of Demographic, Clinical, and Laboratory Characteristics in Predicting the In-Hospital Outcomes of Patients With COVID-19.

Authors:  Diyaa H Bokhary; Nidal H Bokhary; Lamees E Seadawi; Ahlam M Moafa; Hashim H Khairallah; Abdullah Bakhsh
Journal:  Cureus       Date:  2022-03-23

4.  Comparison of laboratory characteristics of gastrointestinal symptoms and nongastrointestinal symptoms in patients infected with COVID-19: a systematic review and meta-analysis.

Authors:  Rui Zhao; Jie Shi; Yichuan Song; Rui Zhang
Journal:  Therap Adv Gastroenterol       Date:  2022-08-22       Impact factor: 4.802

5.  Immune Response, Viral Shedding Time, and Clinical Characterization in COVID-19 Patients With Gastrointestinal Symptoms.

Authors:  Huan Yang; Xiangyu Xi; Weimin Wang; Bing Gu
Journal:  Front Med (Lausanne)       Date:  2021-06-17

Review 6.  Twelve Months with COVID-19: What Gastroenterologists Need to Know.

Authors:  Giulia Concas; Michele Barone; Ruggiero Francavilla; Fernanda Cristofori; Vanessa Nadia Dargenio; Rossella Giorgio; Costantino Dargenio; Vassilios Fanos; Maria Antonietta Marcialis
Journal:  Dig Dis Sci       Date:  2021-07-31       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.